This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Adult polycystic kidney disease - diagnostic considerations

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

How autosomal dominant polycystic kidney disease affects the kidneys (1)

  • 1. Hypertension
  • 2. Acute and chronic pain
  • 3. Cyst and urinary tract infections
  • 4. Haematuria
  • 5. Kidney stones
  • 6. Urine concentration defects
  • 7. Loss of renal function

Cyst enlargement results in an exponential increase in total kidney volume (TKV; expressed relative to height (htTKV)) and often results in ESRD

Clinical symptoms, including early-onset hypertension, abdominal fullness and pain, haematuria and urinary tract infections (UTIs)

  • are usually first observed decades (sometimes even in childhood) before the onset of renal insufficiency

ADPKD diagnosis is made on the basis of imaging.

Age

PKD1 mutation

PKD2 mutation

Unknown ADPKD genotype

15-30 years

>=3 cysts(a)

• PPV = 100%

• SEN = 94.3%

• >=3 cysts (a)

• PPV = 100%

• SEN = 69.5%

• >=3 cysts (a)

• PPV = 100%

• SEN = 81.7%

30-39 years

>=3 cystsa

• PPV = 100%

• SEN = 96.6%

•> =3 cystsa

• PPV=100%

• SEN = 94.9%

• >=3 cystsa

• PPV=100%

• SEN = 95.5%

40-49years

• >=2 cysts in each kidney

• PPV = 100%

• SEN = 92.6%

• >=2 cysts in each kidney

• PPV = 100%

• SEN = 88.8%

• >=2 cysts in each kidney

• PPV = 100%

• SEN = 90%

Advances in renal imaging (magnetic resonance imaging MRI and high-resolution ultrasound) might help with disease exclusion in at-risk individuals. (2)

A study suggested that MRI showing >10 cysts in patients younger than 30 years is 100% sensitive and specific for the diagnosis of ADPKD (3)

Genetic testing is helpful to assess potential living related kidney donors with negative or equivocal scans and detect rare forms of ADPKD and other cystic diseases (4,5).

Prenatal screening. (6)

  • as ADPKD is an adult-onset disease, prenatal screening is not commonly carried out, but there is increasing interest in this procedure, especially from families with experience of early-onset renal disease or early ICAs. Of note, affected families with children with early-onset ADPKD have a high risk of subsequent children also having early and severe ADPKD, and this information should be shared with affected families
  • preimplantation genetic diagnosis is available for ADPKD, including analysis of the duplicated PKD1 locus, and may be more commonly sought in the future

References:

  1. Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018 Dec 6;4(1):50
  2. Pei Y, Obaji J, Dupuis A, et al. Unified criteria for ultrasonographic diagnosis of ADPKD. J Am Soc Nephrol. 2009;20(1):205-212
  3. Pei Y, Hwang Y-H, Conklin J, et al. Imaging-based diagnosis of autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2015;26(3):746-753.
  4. Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018 Dec 6;4(1):50.
  5. Cornec-Le Gall E, Chebib FT, Madsen CD, et al. The value of genetic testing in polycystic kidney diseases illustrated by a family with PKD2 and COL4A1 mutations. Am J Kidney Dis. 2018;72(2):302-308.
  6. Gimpel C, Bergmann C, Bockenhauer D, et al. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Nat Rev Nephrol. 2019 Nov;15(11):713-726.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.